Extrafine Beclometasone Dipropionate/Formoterol NEXThaler on Device Usability, Adherence, Asthma Control and Quality of Life. A Panhellenic Prospective, Non-Interventional Observational Study in Patients with Asthma—The NEXT-Step Study

Extrafine Beclometasone Dipropionate/Formoterol NEXThaler on Device Usability, Adherence, Asthma Control and Quality of Life. A Panhellenic Prospective, Non-Interventional Observational Study in Patients with Asthma—The NEXT-Step Study

Background: The fixed combination of extrafine beclometasone dipropionate 100 μg/formoterol 6 μg (extrafine BDP/F) delivered by NEXThaler has proved to be effective in patients with moderate-to-severe asthma in terms of lung function, symptoms and asthma control. The aim of this study was to investi...

Full description

Bibliographic Details
Main Authors: Petros Bakakos, Panagiotis Chatziapostolou, Panos Katerelos, Petros Efstathopoulos, Aliki Korkontzelou, Paraskevi Katsaounou
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Journal of Personalized Medicine
Subjects:
asthma
NEXThaler
usability
satisfaction
adherence
quality of life
Online Access:https://www.mdpi.com/2075-4426/12/2/146

Internet

https://www.mdpi.com/2075-4426/12/2/146

Similar Items